S14 - Translational and Clinical Advances in Neuro-oncology
Event Time: | Monday May 6, 2019 1:00 pm to 3:00 pm |
Topic(s): | Neuro-oncology |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 2 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
Speaker | Disclosure |
---|
Start Time | Pub. | Title | Presenter |
---|---|---|---|
1:00 PM | 003 | Accelerated progression of IDH mutant glioma after first recurrence |
Disclosure: Dr. Miller has nothing to disclose.
|
1:00 PM | 004 | Clinical and pathological characteristics of 52 adults with H3 K27M-mutant diffuse midline gliomas at UCSF |
Disclosure: Dr. Buerki has nothing to disclose.
|
1:00 PM | 005 | Randomized Prospective Trial of Stereotactic Radiosurgery versus Chemotherapy for Recurrent Malignant Glioma after Second-line Chemotherapy |
Disclosure: Dr. Walbert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Tocagen, and Orbus.
|
1:00 PM | 006 | The Prevalence, Timing, and Prognostic Significance of Glycemic Control as Assessed By Serial Hemoglobin A1c Measurements in Patients with Newly Diagnosed Glioma |
Disclosure: Dr. Williams has nothing to disclose.
|
1:00 PM | 007 | Diffuse Midline and Histone-Mutated Gliomas in Adults: Clinical, Molecular and Radiographic Features |
Disclosure: Dr. Aboud has nothing to disclose.
|
1:00 PM | 008 | Primary dural lymphomas: clinical presentation, management, and outcome in a bi-institutional study |
Disclosure: Dr. Karschnia has nothing to disclose.
|
1:00 PM | 009 | Validating Advanced Volumetric Techniques for Cutaneous Neurofibromas in Clinical Trials |
Disclosure: Dr. Thalheimer has nothing to disclose.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
7:00 AM-9:00 AM |
---|
C5 -
What Do I Do Now?: Neurologic Consultations in Cancer Patients I
Jaishri Blakeley MD |
9:30 AM-11:30 AM |
C17 -
What Do I Do Now?: Neurologic Consultations in Cancer Patients II
Patrick Wen MD, FAAN |
7:00 AM-9:00 AM |
---|
C41 -
Neuro-oncology in 2019: Navigating Current Trends
Maciej Mrugala MD, PhD, MPH, FAAN |
9:15 AM-12:00 PM |
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
11:30 AM-6:30 PM |
P1 -
Poster Session 1
|
3:30 PM-5:30 PM |
C69 -
The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders
Tobias Walbert MD, PhD |
4:45 PM-5:30 PM |
Neuro-oncology Section Guided Poster Tour
|
7:00 AM-9:00 AM |
---|
C81 -
Core Principles of Brain Tumors
Nimish Mohile MD, FAAN |
11:30 AM-6:30 PM |
P2 -
Poster Session 2
|
1:00 PM-3:00 PM |
3:30 PM-5:30 PM |
C110 -
Adult and Pediatric Neuro-Oncology for the Neurohospitalist
Na Tosha Gatson MD, PhD |
9:15 AM-11:30 AM |
---|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
11:30 AM-6:30 PM |
P3 -
Poster Session 3
|
3:30 PM-5:30 PM |
S30 -
Brain Cancer: From Epidemiology to Quality of Life
|
1:00 PM-3:00 PM |
---|
C178 -
Therapy in Neurology I: Neurological Infectious Diseases and Neuro-oncology
Madhu Soni MD, FAAN |
2:00 PM-2:30 PM |
---|
Choosing a Career in Neuro-oncology
Sylvia Kurz MD, PhD |